Skip to content
prognos-logo-light Prognos Health
Main Menu
  • Support
  • Client Login
  • Request Demo
  • prognosFACTOR®
    • Marketplace
  • Products
    • Life Sciences
      • Cohort Designer
      • Patient Journey
      • Physician Segmentation
      • Outcomes
      • Alerts
      • Omnichannel Marketing
    • Payers
      • Underwriting Risk Predictor
      • Risk Adjustment & Quality Analytics
  • Company
    • Careers
    • Events
    • News
    • Insights
  • Contact Us
Home Insights Biomarker Testing in Non-Small Cell Lung Cancer

Biomarker Testing in Non-Small Cell Lung Cancer

  • March 19, 2019
  • Posted in Lab Testing Insights

This post was last updated on November 22, 2019 at 8:50 pm

Lung graphic

By Bill Bowman, Clinical Solutions Architect

The trend toward precision medicine in oncology is epitomized by the management of patients with metastatic non-small cell lung cancer (mNSCLC).  Multiple molecular targets have been identified and a growing number of brands have become commercially available in recent years with activity against cellular proteins or genetic mutations often seen in this tumor type.  Examples include:

  • EGFR mutations
  • EML4/ALK rearrangements
  • ROS1 rearrangements
  • BRAF mutations – also seen in adjuvant/metastatic melanoma and metastatic colorectal cancer (mCRC)
  • PD-L1 expression – also relevant in tumors of the stomach and gastro-esophageal junction, cervix and in urothelial carcinoma, among others

Other newly emerging genetic mutations with applications as therapeutic targets are considered “tumor agnostic”, i.e., they are seen in various cancers. FDA approved brands and agents in clinical development in this category tend to be designed for use in any tumor expressing the genetic mutation in question. These biomarkers may also have application in the treatment of mNSCLC and include mutations of the following:

  • NTRK
  • RET
  • TMB

We propose that testing rates for these various biomarkers in mNSCLC appear to be a function of at least one of the following factors: the length of time since a specific molecular target has been identified and validated by strong clinical evidence; the availability of targeted agents active against the biomarker in question, including the number of approved brands; and the adoption of the appropriate targeted therapy (or therapies) into clinical practice, backed by each brand’s approved label and clinical guidelines from leading medical organizations, e.g., the National Comprehensive Cancer Network (NCCN) or the American Society of Clinical Oncology (ASCO).

This hypothesis has been borne out by analyzing real-world data from Prognos, the industry leader in applying artificial intelligence and machine learning to laboratory data results to identify hard-to-find patients and improve health by predicting disease earlier.   We have examined the two most recent years of laboratory records for multiple biomarkers by leveraging the approximately 45,000 annual patients in the Prognos database with a confirmed diagnosis of mNSCLC.

Our analysis demonstrates that in this tumor type, testing rates are highest for well-established biomarkers such as EGFR mutations, the ALK gene rearrangement and PD-L1.  EGFR was the first biomarker to come into widespread clinical use for mNSCLC and is seen in about 10-15% of patients. A number of brands have become commercially available to treat patients expressing an EGFR mutation.  ALK rearrangements are less common relative to EGFR in this tumor and are seen in perhaps 3-7% of patients, yet six brands are currently FDA-approved for this market segment, plus ALK was the second biomarker to gain traction as an accepted therapeutic target for mNSCLC.  Our data suggests testing rates are similar for EGFR and ALK. PD-L1 is a relatively more recent biomarker, clinically speaking, although over the last few years we have seen a proliferation of high-profile PD-1/PD-L1 immune checkpoint inhibitors, some of which have come to dominate the mNSCLC treatment landscape.  We are also seeing high and expanding rates of PD-L1 testing in this malignancy. As noted above, the availability of a targeted treatment option can also have a strong impact on testing rates. For example, testing for BRAF mutations in mNSCLC was far less frequent vs. the above-referenced biomarkers until the introduction of an FDA-approved drug combination for patients with a particular type of BRAF mutation in this tumor type.  We then noticed a dramatic increase in BRAF testing rates.

At Prognos we have similarly observed a lower testing volume for newer biomarkers such as TMB and NTRK in various tumors, including mNSCLC, although the number of patients being tested has increased steadily over the past year in particular.  Oncologists are less inclined to test for a biomarker unless they have access to the appropriate targeted therapy. The recent launch of a brand that targets NTRK mutations (with other compounds in the pipeline) should lead to a growth in testing, which should expand further as influential medical groups adopt NTRK testing into their guidelines.  Likewise, once the FDA approves brands for mNSCLC that target TMB or RET, we anticipate more oncologists will adopt testing for these biomarkers into their management strategies for this malignancy.

« Rare Disease Day 2019
Available Omnichannel HCP Data Sources »

Categories

  • AI
  • Alerts
  • Clinical
  • Commercial Launch Excellence
  • Disease Awareness
  • Lab Testing Insights
  • Lab Testing Trends
  • Omnichannel Marketing
  • Physician Segmentation
  • Prog Spotlight
  • Technology

Archives

Latest Tweets

Prognos HealthFollow

Prognos Health
prognosAIPrognos Health@prognosAI·
19 Feb

#HealthcareAnalytics are evolving.

On Tuesday February 23, Prognos Health co-founder and CEO, @sundeepbhan, will join @Safeguard for a virtual discussion on the healthcare data revolution with @GKurtzman.

Register: https://us02web.zoom.us/webinar/register/WN_WlCiq5v2TICwSMRi-PVGZw

#HealthcareData #prognosFACTOR

Reply on Twitter 1362875761674354689Retweet on Twitter 1362875761674354689Like on Twitter 1362875761674354689Twitter 1362875761674354689
prognosAIPrognos Health@prognosAI·
11 Feb

Find a way, or make a way. It’s the Prognos mantra embraced by Ali Koc, VP of Engineering at Prognos Health.

In his latest blog post, Ali writes about making data accessible at web speeds, and how it enables data analysis in a truly new way.

https://prognoshealth.com/blog/find-a-way-or-make-a-way-building-an-interactive-analytics-platform-that-speaks-healthcare/

#HealthTech

Reply on Twitter 1359933724088020994Retweet on Twitter 1359933724088020994Like on Twitter 13599337240880209942Twitter 1359933724088020994
prognosAIPrognos Health@prognosAI·
28 Jan

#TBT to our webinar featuring #LifeSciences thought leaders from @Novartis, @TakedaPharma, and @pfizer as well as Prognos Co-founder @jmbhan.

Our latest blog explores 9 insights from these experts for driving #Commercial #LaunchExcellence in #Pharma

https://prognoshealth.com/blog/overheard-at-the-reuters-health-webinar-9-insights-for-driving-commercial-launch-excellence/

Reply on Twitter 1354901342679146499Retweet on Twitter 1354901342679146499Like on Twitter 13549013426791464991Twitter 1354901342679146499
prognosAIPrognos Health@prognosAI·
22 Jan

Uncovering the (Clinical) Truth.

Bill Bowman and @olatulekan write about the intersection where #MachineLearning meets disease-specific #clinical knowledge - #ClinicalTruths - and how this improves #PatientOutcomes with #HealthcareAnalytics at scale.

https://prognoshealth.com/blog/uncovering-the-clinical-truth/

Reply on Twitter 1352709796135391237Retweet on Twitter 13527097961353912371Like on Twitter 13527097961353912373Twitter 1352709796135391237
prognosAIPrognos Health@prognosAI·
31 Dec

As we ring in the new year, there's so much to look forward to. We wish all of our clients, and partners a healthy, happy new year and are excited to continue innovating together in 2021 to positively impact care.

Reply on Twitter 1344647644669468672Retweet on Twitter 1344647644669468672Like on Twitter 13446476446694686722Twitter 1344647644669468672
Load More...
  • prognosFACTOR®
    • Marketplace
  • Products
    • Life Sciences
    • Payers
  • Company
    • Insights
    • Careers
    • Events
    • News
  • LinkedIn
  • Twitter
  • YouTube
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Site Map
© Prognos Health, 2021. All Rights Reserved.

See What Decision Speed Looks Like in Action

To give you the best possible experience, this site uses cookies and by continuing to use the site you agree that we can save them on your device. For more details about cookies and their use, please see our Privacy Policy.